Macular Degeneration Treatment Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
Macular Degeneration is a medical condition that may result in blurred or no vision in the center of the visual field. There may be no symptoms at times at the beginning of macular degeneration, but eventually some people experience a gradual worsening of vision that may affect both or one eye.
MARKET DYNAMICS
The Macular Degeneration Treatment Market is anticipated to grow in the forecast period owing to driving factors such as increasing population of geriatric patients, rising patient population suffering from Macular Degeneration, growing awareness about drugs for treating AMD, introduction on new therapies, improving healthcare as well as healthcare infrastructure, and increase in prevalence and incidence of retinal disorders. Nevertheless, continuous pressure from some key players in binding the usage of different drugs for wet AMD and intrusive administration methods is expected to restrict the market growth during the forecast period.
MARKET SCOPE
The "Global Macular Degeneration Treatment Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Macular Degeneration Treatment Market with detailed market segmentation by Disease Indication, Drug Class, End User and geography. The global Macular Degeneration Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Macular Degeneration Treatment Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Macular Degeneration Treatment Market is segmented on the basis of Disease Indication, Drug Class and End User. Based on Disease Indication the market is segmented into Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment and Others. Based on Drug Class the market is segmented into Anti-Vascular endothelial growth factor and Others. Based on End User the market is segmented into Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals.
REGIONAL FRAMEWORKThe report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Macular Degeneration Treatment Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Macular Degeneration Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Macular Degeneration Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Macular Degeneration Treatment Market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Macular Degeneration Treatment Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Macular Degeneration Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Macular Degeneration Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Macular Degeneration Treatment Market in these regions.
MARKET PLAYERSThe reports cover key developments in the Macular Degeneration Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Macular Degeneration Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Macular Degeneration Treatment Market in the global market. Below mentioned is the list of few companies engaged in the Macular Degeneration Treatment Market.
The report also includes the profiles of key Macular Degeneration Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development In Past Five Years.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Neurotech Pharmaceuticals, Inc
- Ophthotech Corporation
- F. Hoffmann-La Roche Ltd
- StemCells Inc
- Pfizer, Inc
- Sanofi
- Santen Pharmaceuticals
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Macular Degeneration Treatment Market - By Disease Indication
1.3.2 Macular Degeneration Treatment Market - By Drug Class
1.3.3 Macular Degeneration Treatment Market - By End User
1.3.4 Macular Degeneration Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. MACULAR DEGENERATION TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MACULAR DEGENERATION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MACULAR DEGENERATION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET OVERVIEW
6.2. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
7.1. OVERVIEW
7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
7.3. DRY AGE-RELATED MACULAR DEGENERATION TREATMENT
7.3.1. Overview
7.3.2. Dry Age-related macular degeneration treatment Market Forecast and Analysis
7.4. WET AGE-RELATED MACULAR DE-GENERATION TREATMENT
7.4.1. Overview
7.4.2. Wet age-related macular de-generation treatment Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
8.3.1. Overview
8.3.2. Anti-Vascular endothelial growth factor Market Forecast and Analysis
8.4. OTHERS
8.4.1. Overview
8.4.2. Others Market Forecast and Analysis
9. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. AMBULATORY SURGICAL CENTERS
9.3.1. Overview
9.3.2. Ambulatory Surgical Centers Market Forecast and Analysis
9.4. OPHTHALMIC CLINICS
9.4.1. Overview
9.4.2. Ophthalmic Clinics Market Forecast and Analysis
9.5. HOSPITALS.
9.5.1. Overview
9.5.2. Hospitals. Market Forecast and Analysis
10. MACULAR DEGENERATION TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Macular Degeneration Treatment Market Overview
10.1.2 North America Macular Degeneration Treatment Market Forecasts and Analysis
10.1.3 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.1.4 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.1.5 North America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Macular Degeneration Treatment Market
10.1.6.1.1 United States Macular Degeneration Treatment Market by Disease Indication
10.1.6.1.2 United States Macular Degeneration Treatment Market by Drug Class
10.1.6.1.3 United States Macular Degeneration Treatment Market by End User
10.1.6.2 Canada Macular Degeneration Treatment Market
10.1.6.2.1 Canada Macular Degeneration Treatment Market by Disease Indication
10.1.6.2.2 Canada Macular Degeneration Treatment Market by Drug Class
10.1.6.2.3 Canada Macular Degeneration Treatment Market by End User
10.1.6.3 Mexico Macular Degeneration Treatment Market
10.1.6.3.1 Mexico Macular Degeneration Treatment Market by Disease Indication
10.1.6.3.2 Mexico Macular Degeneration Treatment Market by Drug Class
10.1.6.3.3 Mexico Macular Degeneration Treatment Market by End User
10.1.6.4 US Macular Degeneration Treatment Market
10.1.6.4.1 US Macular Degeneration Treatment Market by Disease Indication
10.1.6.4.2 US Macular Degeneration Treatment Market by Drug Class
10.1.6.4.3 US Macular Degeneration Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Macular Degeneration Treatment Market Overview
10.2.2 Europe Macular Degeneration Treatment Market Forecasts and Analysis
10.2.3 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.2.4 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Macular Degeneration Treatment Market
10.2.6.1.1 Germany Macular Degeneration Treatment Market by Disease Indication
10.2.6.1.2 Germany Macular Degeneration Treatment Market by Drug Class
10.2.6.1.3 Germany Macular Degeneration Treatment Market by End User
10.2.6.2 France Macular Degeneration Treatment Market
10.2.6.2.1 France Macular Degeneration Treatment Market by Disease Indication
10.2.6.2.2 France Macular Degeneration Treatment Market by Drug Class
10.2.6.2.3 France Macular Degeneration Treatment Market by End User
10.2.6.3 Italy Macular Degeneration Treatment Market
10.2.6.3.1 Italy Macular Degeneration Treatment Market by Disease Indication
10.2.6.3.2 Italy Macular Degeneration Treatment Market by Drug Class
10.2.6.3.3 Italy Macular Degeneration Treatment Market by End User
10.2.6.4 Spain Macular Degeneration Treatment Market
10.2.6.4.1 Spain Macular Degeneration Treatment Market by Disease Indication
10.2.6.4.2 Spain Macular Degeneration Treatment Market by Drug Class
10.2.6.4.3 Spain Macular Degeneration Treatment Market by End User
10.2.6.5 United Kingdom Macular Degeneration Treatment Market
10.2.6.5.1 United Kingdom Macular Degeneration Treatment Market by Disease Indication
10.2.6.5.2 United Kingdom Macular Degeneration Treatment Market by Drug Class
10.2.6.5.3 United Kingdom Macular Degeneration Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Macular Degeneration Treatment Market Overview
10.3.2 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.3.4 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Macular Degeneration Treatment Market
10.3.6.1.1 Australia Macular Degeneration Treatment Market by Disease Indication
10.3.6.1.2 Australia Macular Degeneration Treatment Market by Drug Class
10.3.6.1.3 Australia Macular Degeneration Treatment Market by End User
10.3.6.2 China Macular Degeneration Treatment Market
10.3.6.2.1 China Macular Degeneration Treatment Market by Disease Indication
10.3.6.2.2 China Macular Degeneration Treatment Market by Drug Class
10.3.6.2.3 China Macular Degeneration Treatment Market by End User
10.3.6.3 India Macular Degeneration Treatment Market
10.3.6.3.1 India Macular Degeneration Treatment Market by Disease Indication
10.3.6.3.2 India Macular Degeneration Treatment Market by Drug Class
10.3.6.3.3 India Macular Degeneration Treatment Market by End User
10.3.6.4 Japan Macular Degeneration Treatment Market
10.3.6.4.1 Japan Macular Degeneration Treatment Market by Disease Indication
10.3.6.4.2 Japan Macular Degeneration Treatment Market by Drug Class
10.3.6.4.3 Japan Macular Degeneration Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Macular Degeneration Treatment Market Overview
10.4.2 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.4.4 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Macular Degeneration Treatment Market
10.4.6.1.1 South Africa Macular Degeneration Treatment Market by Disease Indication
10.4.6.1.2 South Africa Macular Degeneration Treatment Market by Drug Class
10.4.6.1.3 South Africa Macular Degeneration Treatment Market by End User
10.4.6.2 Saudi Arabia Macular Degeneration Treatment Market
10.4.6.2.1 Saudi Arabia Macular Degeneration Treatment Market by Disease Indication
10.4.6.2.2 Saudi Arabia Macular Degeneration Treatment Market by Drug Class
10.4.6.2.3 Saudi Arabia Macular Degeneration Treatment Market by End User
10.4.6.3 U.A.E Macular Degeneration Treatment Market
10.4.6.3.1 U.A.E Macular Degeneration Treatment Market by Disease Indication
10.4.6.3.2 U.A.E Macular Degeneration Treatment Market by Drug Class
10.4.6.3.3 U.A.E Macular Degeneration Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Macular Degeneration Treatment Market Overview
10.5.2 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis
10.5.3 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.5.4 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Macular Degeneration Treatment Market
10.5.6.1.1 Brazil Macular Degeneration Treatment Market by Disease Indication
10.5.6.1.2 Brazil Macular Degeneration Treatment Market by Drug Class
10.5.6.1.3 Brazil Macular Degeneration Treatment Market by End User
10.5.6.2 Argentina Macular Degeneration Treatment Market
10.5.6.2.1 Argentina Macular Degeneration Treatment Market by Disease Indication
10.5.6.2.2 Argentina Macular Degeneration Treatment Market by Drug Class
10.5.6.2.3 Argentina Macular Degeneration Treatment Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MACULAR DEGENERATION TREATMENT MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BAYER AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. NEUROTECH PHARMACEUTICALS, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. OPHTHOTECH CORPORATION
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. STEMCELLS INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PFIZER, INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SANOFI
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANTEN PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Neurotech Pharmaceuticals, Inc
- Ophthotech Corporation
- F. Hoffmann-La Roche Ltd
- StemCells Inc
- Pfizer, Inc
- Sanofi
- Santen Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For